References
- Cagnacci A. Hormonal contraception: venous and arterial disease. Eur J Contracept Reprod Health Care. 2017;22(3):191–199.
- Fruzzetti F, Bitzer J. Review of clinical experience with estradiol in combined oral contraceptives. Contraception. 2010;81(1):8–15.
- Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin Drug Metab Toxicol. 2016;12(7):779–787.
- Lidegaard O, Nielsen LH, Skovlund CW, et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ. 2012;344:e2990.
- Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–339.
- Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017;22(4):245–246.
- Dinger J, Möhner S, Heinemann K. Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: results from the extended INAS-SCORE study. Front Women’s Health. 2020;5:1–8.
- Reed S, Koro C, DiBello J, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care. 2021;26(6):439–446.
- Martínez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007;12(2):97–106.
- Trenor CC, 3rd, Chung RJ, Michelson AD, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347–357.
- Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699.
- Grandi G, Del Savio MC, Lopes da Silva-Filho A, et al. Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Rev Clin Pharmacol. 2020;13(4):327–330.